Shannon McCue

446 total citations · 1 hit paper
11 papers, 300 citations indexed

About

Shannon McCue is a scholar working on Rheumatology, Ophthalmology and Oncology. According to data from OpenAlex, Shannon McCue has authored 11 papers receiving a total of 300 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Rheumatology, 6 papers in Ophthalmology and 4 papers in Oncology. Recurrent topics in Shannon McCue's work include Ocular Diseases and Behçet’s Syndrome (6 papers), Otitis Media and Relapsing Polychondritis (5 papers) and Retinal and Optic Conditions (2 papers). Shannon McCue is often cited by papers focused on Ocular Diseases and Behçet’s Syndrome (6 papers), Otitis Media and Relapsing Polychondritis (5 papers) and Retinal and Optic Conditions (2 papers). Shannon McCue collaborates with scholars based in United States, Japan and South Korea. Shannon McCue's co-authors include Aung Naing, Elisa Giovannetti, Christian Rolfo, Sue Cheng, Mitsuhiro Takeno, Gülen Hatemi, Alfred Mahr, Mindy Chen, Yusuf Yazıcı and Melike Melikoğlu and has published in prestigious journals such as New England Journal of Medicine, Annals of the Rheumatic Diseases and Current Medical Research and Opinion.

In The Last Decade

Shannon McCue

11 papers receiving 293 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Applications and clinical trial landscape using Toll-like receptor agonists to reduce the toll of cancer

2023 105 citations Christian Rolfo, Elisa Giovannetti et al. npj Precision Oncology profile →

Peers

Countries citing papers authored by Shannon McCue

Since Specialization

Citations

This map shows the geographic impact of Shannon McCue's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shannon McCue with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shannon McCue more than expected).

Fields of papers citing papers by Shannon McCue

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shannon McCue. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shannon McCue. The network helps show where Shannon McCue may publish in the future.

Co-authorship network of co-authors of Shannon McCue

This figure shows the co-authorship network connecting the top 25 collaborators of Shannon McCue. A scholar is included among the top collaborators of Shannon McCue based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shannon McCue. Shannon McCue is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

11 of 11 papers shown

#	Work	Indexed citations
1	1470 START001: a phase 1/2 study of invikafusp alfa (STAR0602), a first-in-class TCR β chain-targeted bispecific antibody, as monotherapy in patients with antigen-rich solid tumors resistant to anti-PD(L)1 2024 ·James L. Gulley, Ryan J. Sullivan, Claire F. Friedman, Guru Sonpavde, Nicholas Tschernia, Mercedes Herrera, Aurélien Marabelle, Shannon McCue, (unknown), Madan Katragadda, Jacques Moisan, (unknown), Rajesh Chopra, Kevin M. Chin, (unknown), Ke Liu, Lillian L. Siu	1
2	LB 02.1 Extending Venous Thromboembolism Secondary Prevention with Apixaban in Cancer Patients. The EVE Trial 2023 ·Research and Practice in Thrombosis and Haemostasis ·Robert D. McBane, Charles L. Loprinzi, Shaker R. Dakhil, Adedayo A. Onitilo, Krishna Gundabolu, Michael J. Drescher, (unknown), (unknown), David García, (unknown), (unknown), Alfonso Tafur, Stanislav Henkin, Charles Kuzma, (unknown), (unknown), Tyler Zemla, Shannon McCue, Damon E. Houghton, Waldemar E. Wysokiński	2
3	Applications and clinical trial landscape using Toll-like receptor agonists to reduce the toll of cancer breakdown → 2023 ·npj Precision Oncology ·Christian Rolfo, Elisa Giovannetti, (unknown), Shannon McCue, Aung Naing	105
4	Impact of apremilast on quality of life in Behçet’s syndrome: analysis of the phase 3 RELIEF study 2022 ·RMD Open ·Gülen Hatemi, Alfred Mahr, Mitsuhiro Takeno, Do Young ‍Kim, Melike Melikoğlu, Sue Cheng, Shannon McCue, Maria Paris, Mindy Chen, Yusuf Yazıcı	8
5	A Phase III Randomized Study of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, for Active Ankylosing Spondylitis 2021 ·The Journal of Rheumatology ·Peter C. Taylor, Désirée van der Heijde, Robert Landewé, Shannon McCue, Sue Cheng, Annelies Boonen	11
6	Apremilast for oral ulcers associated with active Behçet's syndrome over 68 weeks: long-term results from a phase 3 randomised clinical trial 2021 ·Clinical and Experimental Rheumatology ·Gülen Hatemi, Alfred Mahr, Mitsuhiro Takeno, Do Young ‍Kim, David Saadoun, Haner Di̇reskeneli̇, Melike Melikoğlu, Sue Cheng, Shannon McCue, Maria Paris, Mindy Chen, Yusuf Yazıcı	17
7	Apremilast for oral ulcers associated with active Behçet's syndrome over 68 weeks: long-term results from a phase 3 randomised clinical trial. 2021 ·Clinical and Experimental Rheumatology ·Gülen Hatemi, Alfred Mahr, Mitsuhiro Takeno, Do Young ‍Kim, David Saadoun, Haner Di̇reskeneli̇, Melike Melikoğlu, Sue Cheng, Shannon McCue, Maria Paris, Mindy Chen, Yusuf Yazıcı	5
8	OP0146 EFFICACY OF APREMILAST FOR ORAL ULCERS ASSOCIATED WITH ACTIVE BEHÇET'S SYNDROME OVER 64 WEEKS: RESULTS FROM A PHASE III STUDY 2019 ·Annals of the Rheumatic Diseases ·Gülen Hatemi, Alfred Mahr, Mitsuhiro Takeno, Do Young ‍Kim, David Saadoun, Haner Di̇reskeneli̇, Sue Cheng, Shannon McCue, Maria Paris, Mindy Chen, Yusuf Yazıcı	2
9	Trial of Apremilast for Oral Ulcers in Behçet’s Syndrome 2019 ·New England Journal of Medicine ·Gülen Hatemi, Alfred Mahr, Yoshiaki Ishigatsubo, Yeong-Wook Song, Mitsuhiro Takeno, Do Young ‍Kim, Melike Melikoğlu, Sue Cheng, Shannon McCue, Maria Paris, Mindy Chen, Yusuf Yazıcı	122
10	OP0082 Apremilast for behÇet's syndrome: a phase iii randomised, placebo-controlled, double-blind study (RELIEF) 2018 ·Annals of the Rheumatic Diseases ·Gülen Hatemi, Alfred Mahr, Mitsuhiro Takeno, (unknown), Melike Melikoğlu, Susanna Cheng, Shannon McCue, Maria Paris, (unknown), Yusuf Yazıcı	5
11	Non-clinical pharmacology, pharmacokinetics, and safety findings for the antihistamine bepotastine besilate 2010 ·Current Medical Research and Opinion ·Jon I. Williams, James A. Gow, (unknown), Shannon McCue, Anne Marie Salapatek, (unknown)	22

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact